---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-26-000032"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:28:11.346328+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcus Q1 net loss $128M, cash $876M; discontinues Phase 3 STAR-121 in NSCLC

## Summary
- Net loss $128M for Q1 2026 vs $112M Q1 2025; revenue $17M down from $28M.
- Cash $876M at Mar 31, 2026, down from $1.0B at Dec 31, 2025; expect ~$600M year-end, runway to H2 2028.
- Discontinued Phase 3 STAR-121 (domvanalimab) in NSCLC after futility analysis (OS not improved vs pembrolizumab+chemo).
- Pipeline: casdatifan Phase 3 PEAK-1 enrolling; 1L Phase 3 initiation expected year-end; new I&I candidate AB102 entering clinic Q3 2026.

## SEC filing metadata
- accession: 0001724521-26-000032
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000032/0001724521-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000032/rcus-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-26-000032
- JSON: https://secwatch.observer/filing/0001724521-26-000032.json
- Plain text: https://secwatch.observer/filing/0001724521-26-000032.txt

## Source-grounded claims
- claim_id: 70edd838d1fcc5fd5dddbb9cecc7532c448a2b67
  claim: Arcus Biosciences, Inc. reported financial results for three months ended March 31, 2026.
  evidence_excerpt: On May 5, 2026 , Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000032/0001724521-26-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.